3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
9
Nivolumab
4
Fluorouracil
4
Mohs Surgery
3
talimogene laherparepvec
2
atezolizumab
2
Therapeutics
2
Photochemotherapy
2
Petrolatum
2
Paclitaxel
2
Niacinamide
2
Aminolevulinic Acid
2
tozuleristide
1
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
1
selinexor
1
regorafenib
1
peginterferon alfa-2b
1
peginterferon alfa-2a
1
osimertinib
1
nanocis
1
methyl 5-aminolevulinate
1
fludarabine
1
daromun
1
cobimetinib
1
cemiplimab
1
avelumab
1
aldesleukin
1
aflibercept
1
afamelanotide
1
Vitamin D
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
nanocis
×
Dermatologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled